2001
Reply to Comments on "Olanzapine Treatment of Children, Adolescents, and Adults With Pervasive Developmental Disorders: An Open-Label Pilot Study"
Potenza M, McDougle C. Reply to Comments on "Olanzapine Treatment of Children, Adolescents, and Adults With Pervasive Developmental Disorders: An Open-Label Pilot Study". Journal Of Clinical Psychopharmacology 2001, 21: 246-247. PMID: 11270929, DOI: 10.1097/00004714-200104000-00024.Peer-Reviewed Original Research
1999
Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental Disorders
Potenza M, Holmes J, Kanes S, McDougle C. Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental Disorders. Journal Of Clinical Psychopharmacology 1999, 19: 37-44.. PMID: 9934941, DOI: 10.1097/00004714-199902000-00008.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderClinical Global Impression ScaleWeight gainTolerability of olanzapineLiver function abnormalitiesExtrapyramidal side effectsGlobal Impression ScaleGlobal improvement itemTreatment of childrenSignificant adverse effectsDevelopmental disordersSelf-injurious behaviorClinical respondersOlanzapine treatmentFunction abnormalitiesDaily doseOverall symptomsPatient populationImpression ScalePrincipal diagnosisMotor restlessnessProspective fashionWeek 4Related symptomsSide effects